JPH1036346A5 - - Google Patents

Info

Publication number
JPH1036346A5
JPH1036346A5 JP1997101563A JP10156397A JPH1036346A5 JP H1036346 A5 JPH1036346 A5 JP H1036346A5 JP 1997101563 A JP1997101563 A JP 1997101563A JP 10156397 A JP10156397 A JP 10156397A JP H1036346 A5 JPH1036346 A5 JP H1036346A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
azepan
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997101563A
Other languages
English (en)
Japanese (ja)
Other versions
JP4093611B2 (ja
JPH1036346A (ja
Filing date
Publication date
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed filed Critical
Publication of JPH1036346A publication Critical patent/JPH1036346A/ja
Publication of JPH1036346A5 publication Critical patent/JPH1036346A5/ja
Application granted granted Critical
Publication of JP4093611B2 publication Critical patent/JP4093611B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP10156397A 1996-04-19 1997-04-18 エストロゲン剤 Expired - Lifetime JP4093611B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US08/833271 1997-04-04
US08/633974 1997-04-04

Publications (3)

Publication Number Publication Date
JPH1036346A JPH1036346A (ja) 1998-02-10
JPH1036346A5 true JPH1036346A5 (enExample) 2008-02-14
JP4093611B2 JP4093611B2 (ja) 2008-06-04

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10156397A Expired - Lifetime JP4093611B2 (ja) 1996-04-19 1997-04-18 エストロゲン剤

Country Status (26)

Country Link
EP (1) EP0802183B1 (enExample)
JP (1) JP4093611B2 (enExample)
KR (1) KR100480193B1 (enExample)
CN (1) CN1106383C (enExample)
AR (1) AR011503A1 (enExample)
AT (1) ATE206701T1 (enExample)
AU (1) AU710149B2 (enExample)
BR (1) BRPI9715334B8 (enExample)
CO (1) CO4900051A1 (enExample)
CY (2) CY2325B1 (enExample)
CZ (1) CZ291701B6 (enExample)
DE (2) DE122009000061I1 (enExample)
DK (1) DK0802183T3 (enExample)
EA (1) EA001448B1 (enExample)
ES (1) ES2162198T3 (enExample)
FR (1) FR09C0048I2 (enExample)
HU (1) HU227077B1 (enExample)
IL (1) IL120701A (enExample)
LU (1) LU91608I2 (enExample)
MX (1) MX9702865A (enExample)
NL (1) NL300416I2 (enExample)
NO (2) NO309564B1 (enExample)
NZ (1) NZ314601A (enExample)
PT (1) PT802183E (enExample)
SK (1) SK281737B6 (enExample)
UA (1) UA48148C2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523254A (ja) 1997-04-30 2001-11-20 イーライ・リリー・アンド・カンパニー 抗血栓剤
ATE253359T1 (de) 1997-05-01 2003-11-15 Lilly Co Eli Antithrombotische mittel
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
AU3894399A (en) * 1998-05-12 1999-11-29 American Home Products Corporation Benzocarbazole and indenoindole derived estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
EP1080073A1 (en) * 1998-05-15 2001-03-07 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
AP1424A (en) * 1998-05-15 2005-06-06 Wyeth Corp 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE69914563T2 (de) 1998-10-30 2004-12-16 Eli Lilly And Co., Indianapolis Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
CN1342144A (zh) * 1999-03-04 2002-03-27 美国家用产品公司 用作雌激素药物的n－取代的苯甲酰基吲哚类化合物
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
BR0013943A (pt) * 1999-09-13 2002-05-14 American Home Prod Conjugados de glicopiranosìdeos de 2-(4-hidróxi-fenil)-1-[4-(2-amin-1-il-etóxi)-benzil]-1h-indo l-5-óis
EP1251855A1 (en) * 2000-01-28 2002-10-30 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
JP2004502729A (ja) * 2000-07-06 2004-01-29 ワイス Ｓｓｒｉおよびエストロゲン剤の組み合わせ
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
US6509332B2 (en) 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
WO2002003988A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
EP1296674A2 (en) * 2000-07-06 2003-04-02 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AU2001271706A1 (en) * 2000-07-06 2002-01-21 American Home Products Corporation Use of substituted indole compounds for treating breast disorders
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
EP1401446B1 (en) 2001-05-22 2005-02-09 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
RU2355397C2 (ru) * 2002-06-13 2009-05-20 Уайт Режимы лечения базедоксифеном
PL374845A1 (en) 2002-07-22 2005-11-14 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
TW200536845A (en) 2004-04-07 2005-11-16 Wyeth Corp Crystalline polymorph of bazedoxifene acetate
RU2006132180A (ru) 2004-04-07 2008-05-20 Вайет (Us) Кристаллический полиморф базедоксифен ацетата
BRPI0509385A (pt) 2004-04-08 2007-09-18 Wyeth Corp composto, composição, métodos de preparar o sal, ea dispensão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência de estrogênio ou excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal dos tecidos endometriais, de tratar cáncer de mama em um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, dispersão sólida, e, uso de um composto
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
WO2006017639A2 (en) * 2004-08-05 2006-02-16 Wyeth Crystalline polymorph of pipindoxifene hydrochloride monohydrate
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
EP2252585B1 (en) * 2008-02-11 2013-11-06 Wyeth LLC Methods of preparing polymorphic form a of bazedoxifene acetate
RS54165B1 (sr) 2008-04-16 2015-12-31 Karo Bio Ab Novi ligandi za estrogenski receptor
JP2012523445A (ja) * 2009-04-13 2012-10-04 サンド・アクチエンゲゼルシヤフト バゼドキシフェン酢酸塩およびその中間体を合成するための方法
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
SG186333A1 (en) 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
US9212172B2 (en) 2010-09-14 2015-12-15 Dr. Reddy's Laboratories Limited Preparation of crystalline bazedoxifene and its salts
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
WO2014186325A1 (en) * 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU373941A3 (enExample) * 1970-01-21 1973-03-12
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
ATE188377T1 (de) * 1993-06-29 2000-01-15 Takeda Chemical Industries Ltd Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Similar Documents

Publication Publication Date Title
HUP0101434A3 (en) Sulfonamide-containing indole compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
JPH11514367A5 (enExample)
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
NO2005009I1 (no) Emselex-Darifenacin-IUPAC-nabn: (S)-2-(1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜ3-pyrrolidinylÜ-2,2-difenylacetamid
NO972679L (no) Fremgangsmåte for fremstilling av 1-(2'-deoksy-2',2'-difluor-D-ribofuranosyl-4-aminopyrimidin-2-on)hydroklorid
HUP9700777A3 (en) Estrogenical 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives, preparation and use thereof and pharmaceutical compositions containing these compounds
MA26523A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-(2-(2-methoxyphenoxy) ethylamino)-2-propanole, procede pour sa preparation et compositions pharmaceutiques le comprenant
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ZA9911B (en) 2,3-substituted indole compounds as anti-inflammatory and analgesic agents.
WO1999044608A8 (en) New use
NO970036D0 (no) Nytt oralt, farmasöytisk preparat inneholdende magnesiumsalt av omeprazol
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
ZA200201521B (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
FR2793688B1 (fr) Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IT1274571B (it) Procedimento per la preparazione di ¬r-(r*,r*)|-5-(3-clorofenil)-3- ¬2-(3,4-dimetossifenil)-1-metil-etil|-ossazolidin-2-one
FI964212A7 (fi) Röntgenvarjoainekoostumuksia, jotka sisältävät farmaseuttisesti hyväks yttäviä savia
NO20033184L (no) Anvendelse av forbindelsen (+)-<alfa>-(2,3-dimetoksyfenyl)-1- [2-(4-fluorfenyl)etyl]-4-piperidinmetanol
NO20004545D0 (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
NO980211D0 (no) Opplösning av 1-azabicyklo£2.2.2|oktan-3-amin,2-(difenylmetyl)-N-££2-metoksy-5-(1-metyletyl)fenyl|metyl|
ZA979411B (en) The use of lithium compounds for combatting human papilloma virus infections.
HUP9901030A3 (en) Substituted n-methyl-n-(4-(4-(1h-benzimidazol-2-yl-amino)piperidin-1-yl)-2-(aryl)butyl)benzamid derivatives, pharmaceutical compositions containing these compounds and use thereof
EP1245562A4 (en) ALCOHOLS 5-THIA- "OMEGA" - (PHENYL SUBSTITUTED) - PROSTAGLANDIN E, PROCESS FOR THE PREPARATION OF SUCH ALCOHOLS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE ALCOHOLS AS ACTIVE INGREDIENT.
AU2253197A (en) Novel substituted N-Methyl-N-(4-(4-(1H-benzimidazol- 2-yl){1,4}diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
AU6476700A (en) Process for the preparation of indole derivatives or salts thereof
BG105289A (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders